Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting
- PMID: 27998397
- PMCID: PMC5422023
- DOI: 10.5483/bmbrep.2017.50.3.222
Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting
Abstract
Most of the cancers are still incurable human diseases. According to recent findings, especially targeting cancer stem cells (CSCs) is the most promising therapeutic strategy. CSCs take charge of a cancer hierarchy, harboring stem cell-like properties involving self-renewal and aberrant differentiation potential. Most of all, the presence of CSCs is closely associated with tumorigenesis and therapeutic resistance. Despite the numerous efforts to target CSCs, current anti-cancer therapies are still impeded by CSC-derived cancer malignancies; increased metastases, tumor recurrence, and even acquired resistance against the anti-CSC therapies developed in experimental models. One of the most forceful underlying reasons is a "cancer heterogeneity" due to "CSC plasticity". A comprehensive understanding of CSC-derived heterogeneity will provide novel insights into the establishment of efficient targeting strategies to eliminate CSCs. Here, we introduce findings on mechanisms of CSC reprogramming and CSC plasticity, which give rise to phenotypically varied CSCs. Also, we suggest concepts to improve CSC-targeted therapy in order to overcome therapeutic resistance caused by CSC plasticity and heterogeneity. [BMB Reports 2017; 50(3): 117-125].
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures
Similar articles
-
Cancer stem cell (a)symmetry & plasticity: Tumorigenesis and therapy relevance.Life Sci. 2019 Aug 15;231:116520. doi: 10.1016/j.lfs.2019.05.076. Epub 2019 May 31. Life Sci. 2019. PMID: 31158379 Review.
-
Stem cell programs in cancer initiation, progression, and therapy resistance.Theranostics. 2020 Jul 9;10(19):8721-8743. doi: 10.7150/thno.41648. eCollection 2020. Theranostics. 2020. PMID: 32754274 Free PMC article. Review.
-
Pancreatic cancer stem cells: A state or an entity?Semin Cancer Biol. 2018 Dec;53:223-231. doi: 10.1016/j.semcancer.2018.08.007. Epub 2018 Aug 18. Semin Cancer Biol. 2018. PMID: 30130664 Review.
-
Hypoxia in solid tumors: a key promoter of cancer stem cell (CSC) resistance.J Cancer Res Clin Oncol. 2020 Jan;146(1):19-31. doi: 10.1007/s00432-019-03080-1. Epub 2019 Nov 16. J Cancer Res Clin Oncol. 2020. PMID: 31734836 Review.
-
Cell plasticity, senescence, and quiescence in cancer stem cells: Biological and therapeutic implications.Pharmacol Ther. 2022 Mar;231:107985. doi: 10.1016/j.pharmthera.2021.107985. Epub 2021 Sep 1. Pharmacol Ther. 2022. PMID: 34480963 Free PMC article. Review.
Cited by
-
Identification and validation of SNHG gene signature to predict malignant behaviors and therapeutic responses in glioblastoma.Front Immunol. 2022 Sep 8;13:986615. doi: 10.3389/fimmu.2022.986615. eCollection 2022. Front Immunol. 2022. PMID: 36159816 Free PMC article.
-
The Oncoprotein Fra-2 Drives the Activation of Human Endogenous Retrovirus Env Expression in Adult T-Cell Leukemia/Lymphoma (ATLL) Patients.Cells. 2024 Sep 10;13(18):1517. doi: 10.3390/cells13181517. Cells. 2024. PMID: 39329701 Free PMC article.
-
Amino Acid-Mediated Metabolism: A New Power to Influence Properties of Stem Cells.Stem Cells Int. 2019 Dec 5;2019:6919463. doi: 10.1155/2019/6919463. eCollection 2019. Stem Cells Int. 2019. PMID: 31885621 Free PMC article. Review.
-
Dissecting Tumor Growth: The Role of Cancer Stem Cells in Drug Resistance and Recurrence.Cancers (Basel). 2022 Feb 15;14(4):976. doi: 10.3390/cancers14040976. Cancers (Basel). 2022. PMID: 35205721 Free PMC article. Review.
-
Cancer Stem Cell Plasticity - A Deadly Deal.Front Mol Biosci. 2020 Apr 30;7:79. doi: 10.3389/fmolb.2020.00079. eCollection 2020. Front Mol Biosci. 2020. PMID: 32426371 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources